Treatment of stable angina
1University of Oklahoma Health Sciences Center, Oklahoma City, USA. udhothadani@ouhsc.edu
Current Opinion in Cardiology
|August 17, 1999
Summary
For stable angina pectoris, established treatments reduce symptoms and improve outcomes. However, whether anti-anginal drugs impact adverse clinical events remains unknown, necessitating further research.
Area of Science:
- Cardiology
- Internal Medicine
Background:
- Stable angina pectoris is primarily caused by atherosclerotic narrowing of coronary arteries, leading to myocardial ischemia.
- Nonobstructive plaques in coronary arteries pose a risk for acute coronary syndromes.
- Current treatment focuses on symptomatic relief and reducing adverse outcomes like coronary death and myocardial infarction.
Purpose of the Study:
- To investigate the impact of established medical therapies on reducing adverse clinical outcomes in patients with stable angina pectoris.
- To determine if anti-anginal drugs (beta-blockers, long-acting nitrates, calcium channel blockers) affect adverse outcomes in stable angina.
- To evaluate the superiority of suppressing ambulatory myocardial ischemia versus symptom-relief pharmacologic therapy.
Main Methods:
- Review of established treatments including smoking cessation, aspirin, lipid management, and blood pressure control.
- Analysis of the role of beta-blockers and angiotensin-converting enzyme inhibitors in patients with reduced left ventricular function.
- Examination of recent trials evaluating ambulatory ischemia suppression and anti-anginal agent efficacy on outcomes.
Main Results:
- The benefits of smoking cessation, aspirin, lipid control, and hypertension management in reducing adverse outcomes are well-established.
- Beta-blockers and ACE inhibitors are beneficial for patients with diminished left ventricular systolic function.
- The effect of anti-anginal drugs on adverse clinical outcomes in stable angina remains undetermined.
Conclusions:
- While several interventions reduce symptoms and improve outcomes in stable angina, the specific impact of anti-anginal drugs on adverse events is unknown.
- Further research is needed to establish whether suppressing ambulatory ischemia with anti-anginal agents or revascularization is superior to symptom-focused pharmacologic therapy.
- Emerging techniques for refractory angina require validation through large randomized clinical trials.
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:27Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
01:29Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:20Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...